NAD supplementation to improve brain vascular health in older adults
Effects of NAD Restoration on Neurovascular Coupling in Community Dwelling Older Adults
This study is testing if a vitamin called Nicotinamide Riboside can help improve brain health and memory in older adults by boosting a key molecule in the brain.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 214 (estimated) |
| Ages | 60 Years to 85 Years |
| Sex | All |
| Sponsor | University of Oklahoma Academic / other |
| Locations | 1 site (Oklahoma City, Oklahoma) |
| Trial ID | NCT05483465 on ClinicalTrials.gov |
What this trial studies
This study tests whether Nicotinamide Riboside (NR), a form of Vitamin B3, can enhance brain health and memory in older adults by restoring levels of Nicotinamide Adenine Dinucleotide (NAD). Participants aged 60 to 85 will receive either NR or a placebo for 8 weeks, with assessments focused on neurovascular coupling and endothelial function. The study aims to determine if daily NR supplementation can lead to significant improvements in brain vascular health.
Who should consider this trial
Good fit: Ideal candidates are community-dwelling older adults aged 60 to 85 who can provide informed consent and have adequate cognitive function.
Not a fit: Patients with active CNS diseases, major psychiatric disorders, or significant kidney or liver dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to new strategies for improving brain health and memory in aging populations.
How similar studies have performed: Other studies have shown promising results with NAD supplementation, but this specific approach in older adults is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥60 and ≤85 years of age * Adequate hearing and visual acuity to participate in the examinations * Ability to read and write in English * Competence to provide informed consent. * Mini-Mental State Exam score ≥24 Exclusion Criteria: * Vision or hearing impairment that would impair the ability to complete study assessments * Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer * Cerebrovascular accident other than TIA within 60 days prior to Visit 0 * Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse * Abnormal kidney function (creatinine \>2mg/dL or EGFR \<30mL/min) by most recent labs within 6 months prior to Visit 0 * Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by most recent labs within 6 months prior to Visit 0 * Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamide mononucleotide) within 4 weeks prior to randomization. * Any other medical condition which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol
Where this trial is running
Oklahoma City, Oklahoma
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States (Recruiting)
Study contacts
- Principal investigator: Andriy Yabluchanskiy, MD, PhD — University of Oklahoma
- Study coordinator: Andriy Yabluchanskiy, MD, PhD
- Email: andriy-yabluchanskiy@ouhsc.edu
- Phone: 405-271-7622
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.